Articles

Flowcytometric and DNA Analysis Minimal Residual Disease (MRD) in Childhood B-Lineage lymphoblastic leukemia

Abstract

Background: Induction Chemotherapy for Acute Lymphoblastic Leukemia achieves complete remis¬sion in over 90% of children. It is apparent therefore that many patients in clinical remission and with¬out residual disease detectable by conventional light microscopy of peripheral blood or bone marrow films still harbor viable cells of the original disease MRD analysis does have a useful role to play in the risk directed treatment of childhood ALL and this is currently being investigated in large prospective studies.
Methods: We have investigated MRD in bone marrow samples by three color flowcytometry approach in 63 pediatric B-precursor ALL patients treated according to BFM ALL 95 protocol. Bone marrow samples were collected from children at three different times including: Day 28th, At the beginning of intensified therapy and at the end of therapy .Cells with leukemia associated Immunophenotype were investigated by DNA analysis for evaluation of DNA content.
Results: Among 63 children with diagnosis of B-lineage ALL and quantified for post induction residual disease study .We observed that the mean number of blast cells have significant differences among these groups. The mean number of Leukemic blasts counted on day 28 was 2.7± 0.4, at the beginning of intensified therapy 1.7±0.4, and at the end of treatment 0.5±.2. These patients were in complete re¬mission in light microscopy examination. Relapse of ALL was demonstrated in six of 63 children (9.5%) whose MRD were more than one blast in 10-2 cells .Comparing this to light microscopic exami¬nation dill of  these patients had 4-5% blasts vs. 1% for those who did not relapse.
Conclusion: MRD analysis does have a useful role in the risk directed treatment of child hood ALL and the investigation of levels and the dynamics of MRD by sensitive and quantitative flowcytometry and PCR methods reduce false negative results. However a good morphology is also valuable.

Pui C-H. Childhood Leukemia: NEJM,1995;332:1618- 30

Gustaffsson G, Schmiegelow K, Forestier E, etal. Im- proving outcome through two decades in childhood ALL in the Nordic countries: the impact of high dose Meth- otrexate in the reduction of CNS irradiation. Leukemia 2000:14; 2267-2275

Evans WE, Relling MV, Rodman JH, etal. Conven- tional compared with individualized chemotherapy for childhood acute Lymphoblastic leukemia: NEJM, 1998:338:499-505

Campana D, Pui CH: Detection of minimal residual disease in acute leukemia. Methodological advances and clinical significance: Blood .1995; 85: 1416 -1434

Foroni L, Harrison C, Hoff brand VA, Potter M: Inves- tigation of minimal residual disease in childhood and adult acute Lymphoblastic leukemia by molecular analy- sis; BRJ Hematol, 1999, 105:7-24

Hoas VDE , Verhagen OJ , Von dem , Borne AEG, etal : Quantification of minimal residual disease with oli- goclonal B-Precursor acute Lymphoblastic leukemia in- dicates that the clones that grow out during relapse al- ready have the slowest rate of reduction during induction therapy . Leukemia. 2001 Jan vol 15, no: 1:134-140

Bjorklund E, Mazur J, Soderhall S, etal: Flowcytomet- ric follow up of minimal residual disease in bone marrow gives prognostic information in children with acute Lym- phoblastic leukemia. Leukemia, 2003, Jan, vol 17, no: 1: 138-148

Mckenna RW, Washington LT, AquinoDB, Picker LJ, Kroft SH: Immunophenotypic analysis (B-Lymphocyte precursors) in 662 consecutive bone marrow specimens by 4 color flowcytometry.Blood, 2001, 15:2498-2507

Dario C, Elain CS: Advances in immunological moni- toring of childhood acute Lymphoblastic leukemia; Best practice &Research clinical clinical hematology.2002; 15:1-19

Neale GA, Coustan-Smith E, Pan Q, etal: Tandem application of flowcytometry and polymerase chain reac- tion for comprehensive detection of minimal residual dis- ease in childhood acute Lymphoblastic leukemia: Leu- kemia; 1999; 13:1221-1226

Gustafson G , Krueger A, Clausen N, Gorwicz S , Kristinsson J, Lie So,Moe Pj, Perkio M,Yssing M, Soarinen P: Intensified treatment of acute childhood Lymphoblastic leukemia has improved prognosis espe- cially in non high risk patients: The 1996 Nordic society of pediatric Hematology and Oncology (NOPHO):Acta Pediatr 1998;87:1151-1161

Sczepanski V, Orfao V, Vandervelden VH, etal: Minimal residual disease in leukemia patients .Lancet Oncology 2001; 2:409-417

Asma GE, Vandenberg RL, Vossen JM: Regeneration of TdT+, Pre b and B cell in bone marrow after allogenic bone marrow transplantation. Transplantation .1987; 43:365-870

Maria BV, Alberto O, Elains CS, Dario C: Minimal residual disease monitoring by flowcytometry.Best prac- tice&Research clinical hematology; 2003 .16.4:599-612

Schrappe M ,Camitta B,Pui CH,Eden T, Gaynon P, Gustafsson G,Janka GE, Kamps N , Masera G, Sallan S , Tsuchida M , Vilmer E : Longterm result of large pro- spective trials in childhood acute Lymphoblastic leuke- mia:leukemia 2000 : 14:2193-2194

Coustan SE, Sancho J, Hancock ML: Use of periph- eral blood instead of bone marrow to monitor residual disease in children with acute Lymphoblastic leukemia: Blood 2002; 100:2399-2402

Jurgen K, Kerstin J, Oliver O: Prognostic value of MRD quantification by real time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemia: JC Oncology 2003, 21, 23:4413-4422

Charlote N, Hanson M, and Lars PR: Precise quanti- fication of minimal residual disease at they 29 allows identification of children with acute Lymphoblastic leu- kemia and an excellent outcome. Blood 2002, 99.4: 1253-1258

Hass VDE, Verhagen OJH, Vondem B: Quantifica- tion of minimal residual disease in children with oligo- clonal (B-precursor acute lymphoblastic leukemia indi- cates the colones that grow out during relapse already have the slowest rate of reduction during induction ther- apy.Leukemia.2001,15, 134-40

Bjorklound G, Mazur J, Soderhall S, Flowcytometric follow up of minimal residual disease in bone marrow gives prognostic information in children with acute lym- phoblastic leukemia. Leukemia.2003, 17,138-148

Dwozac MN, Froschl G, Printz D: Prognostic signifi- cants and modalities of flow cytometric minimal residual disease detection in childhood acute Lymphoblastic leu- kemia.Blood.2002, 99:1952-1958

Files
IssueVol 2, No 2 (2005) QRcode
SectionArticles
Keywords
Minimal Residual Disease DNA analysis
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Vossough P, Faranoush M, Emami Z, Bahoush G, Arjmandi K, Ansari S, Alebouyeh M, Shahgholi E, Hedayatiasl A. Flowcytometric and DNA Analysis Minimal Residual Disease (MRD) in Childhood B-Lineage lymphoblastic leukemia. Int J Hematol Oncol Stem Cell Res. 1;2(2):5-9.